Stock events for Novanta, Inc. (NOVT)
In Q1 2025, Novanta reported increased revenue and net income. Wall Street Zen downgraded Novanta to a "hold" rating, and Robert W. Baird lowered its target price. Zacks Research upgraded Novanta to a "hold" rating. Weiss Ratings downgraded Novanta to "Sell". Novanta shares experienced a price surge attributed to growth in advanced surgery, robotics automation, and new product launches. Novanta's stock underperformed due to weaker revenue growth and concerns regarding med-tech capital equipment and China-linked components.
Demand Seasonality affecting Novanta, Inc.’s stock price
Demand for Novanta's products is influenced by economic cycles and capital spending trends in the medical, life sciences, and industrial sectors. Demand could fluctuate with broader economic conditions and investment cycles within those industries.
Overview of Novanta, Inc.’s business
Novanta, Inc. is a global technology company specializing in precision components, subsystems, and software for photonics and motion control, serving OEMs in medical and industrial markets. The company operates in three segments: Photonics, Vision, and Precision Motion. The Photonics segment focuses on advanced laser technologies and optical solutions. The Vision segment provides advanced imaging and sensing solutions. The Precision Motion segment delivers motion control technologies. Novanta's product portfolio includes medical technologies under brands like JADAK, NDS Surgical Imaging, and Photo Research, and precision motion products under Applimotion, microe, and Westwind.
NOVT’s Geographic footprint
Novanta has a significant international presence with facilities across North America, Europe, and Asia, including manufacturing and technology centers in Germany, Italy, the United Kingdom, China, and Japan. It serves principal geographic markets in North America, Europe, and Asia Pacific.
NOVT Corporate Image Assessment
Novanta's brand reputation is positive, driven by its commitment to innovation and industry leadership. Novanta hosted an ISO working group event focusing on safety standards for humanoid robots. The company's participation in events like the Baird 2025 Global Industrial Conference enhances its reputation. Novanta is recognized for its deep proprietary technology expertise in precision medicine and manufacturing.
Ownership
Institutional investors and hedge funds own a significant portion of Novanta's stock, approximately 98.35%. Major institutional owners include T. Rowe Price Investment Management Inc., Wellington Management Group LLP, and Principal Financial Group Inc. Individual owners (insiders) hold approximately 0.96% of the shares.
Ask Our Expert AI Analyst
Price Chart
$135.86
